<DOC>
	<DOCNO>NCT02325375</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) fatal disease progressive muscle weakness lead severe disability eventually death.Since diagnosis relies clinical feature electromyographic abnormality , may occur rather late disease course , need identify diagnostic test confirm exclude diagnosis ALS early phase disease . More recently , study suggest neuroinflammation play role development ALS . Cluster differentiation 163 found regulate large range inflammatory disease . At investigator lab , pilot data ( Kallestrup M et al , unpublished data ) show promising result . There increased level cluster differentiation 163 ( sCD163 ) cerebrospinal fluid 7 patient ALS compare control . The purpose investigator study define concentration sCD163 cerebrospinal fluid serum patient ALS compare control ( patient unspecified neurological symptom ) . Furthermore , investigator define concentration protein , glucose , immunoglobulin G index factor spinal fluid .</brief_summary>
	<brief_title>sCD163 ALS Patients</brief_title>
	<detailed_description>Introduction Amyotrophic lateral sclerosis ( ALS ) fatal disease progressive muscle weakness lead severe disability eventually death . It common form motor neuron diseases involve upper low motor neuron . The median survival debut symptom dead approximately 3 year . Since diagnosis relies clinical feature electromyographic abnormality , may occur rather late disease course , need identify diagnostic test confirm exclude diagnosis ALS early phase disease . ALS neurodegenerative disease , however pathogenesis well establish . The cause probably multifactorial complex interaction genetic factor dysfunction vital molecular pathway concern dominantly inherit c9orf72 gene impaired glutamate uptake astrocyte ( EAAT2-receptor ) synaptic cleft thereby glutamate excitotoxicity . This glutamate excitotoxicity may cause oxidative stress , voltage-gated persistent sodium channel activation microglia result secretion proinflammatory cytokine . More recently , study suggest neuroinflammation play role development ALS . A study 2012 ( mouse model ALS , overexpress mutant superoxide dismutase ( mSOD1 ) ) , document microglia protect injure motor neurones depend phenotype microglia activate . It seem like continuum protective M2 phenotypic state ( disease onset ) neurotoxic M1 phenotypic state ( disease end-stage ) . Furthermore , disease onset mouse express high level Ym1 , CD163 brain-derived neurotrophic factor ( marker M2 ) . Of molecular mechanism , worth mention structural functional abnormality mitochondrion , impairment axonal transport system endosomal traffic induction endoplasmic reticulum stress response although appear secondary event ALS . The net result degeneration motor neurones cerebral cortex , cranial nerve nucleus , anterior horn spinal cord corticospinal tract . The present treatment available Riluzole proven extend life time onset serious respiratory problem patient ALS . The mode action Riluzole still determine , possibly dynamic inhibition glutamate release presynaptic neuron . ( 1,2,3,4,5,6 ) Though seem inflammatory process secondary event , seem critical neuronal degeneration . In study , ALS pathology seek reduced central nervous system target glucocorticoid succeed reduce brainstem pathology mouse model ALS . Of different biomarkers , inflammatory marker also test : interleukin-1 family cytokine . Among total interleukin-18 , endogenous inhibitor interleukin-18BP , active form cytokine ( free interleukin-18 ) significantly high ALS patient control . The cytokine show correlation different clinical form ALS clinical setting disease . Cytokines also try neuroprotective agent . Erythropoietin ( EPO ) know growth factor maintain number circulate erythrocyte . However , biological role EPO expand cell , neuron , microglia , astrocytes brain . EPO seem suppress proinﬂammatory cytokine disease progression , maintain anti-inﬂammatory cytokine late symptomatic stage finally seem delay symptom onset preserve number motor neuron . ( 7,8,9,10 ) Cluster differentiation 163 ( CD-163 ) - new way monitor inflammation ALS ? CD-163 scavenger receptor ( recognizes uptake macromolecule ) mark monocyte-macrophage activation . CD163 work macrophage receptor hemoglobin-haptoglobin complex . The soluble form receptor call sCD163 find plasma cerebrospinal fluid , find regulate large range inflammatory disease . Strongly increased value ( &gt; 20mg/l ) see disease like macrophage activate syndrome , hemophagocytic syndrome acute hepatic failure . Furthermore , level sCD163 reflect activity disease . Patients increase high value find unfavorable prognosis . Increased value ( 5-20 mg/l ) see hepatic disease , sepsis Gaucher 's disease . Septic patient value great 10 mg/l 10 time great risk fatal outcome . Values increase little ( 3-5 mg/l ) often see inflammatory infectious condition cancer . ( 11,12,13,14 ) Pilot data At investigator lab , pilot data ( Kallestrup M et al , unpublished data ( 15 ) ) show promising result . There increased level sCD163 cerebrospinal fluid 7 patient ALS compare control . Furthermore , definite probable ALS patient increase level sCD163 . These result suggest large study perform evaluate patient ALS early well later stag disease . Hypothesis Patients ALS up-regulated level sCD-163 cerebrospinal fluid serum compare healthy subject level related severity disease . Purpose To define concentration sCD-163 cerebrospinal fluid serum patient ALS compare control ( patient unspecified neurological symptom ) . Furthermore , define concentration protein , glucose , immunoglobulin G index factor spinal fluid . Method Study population The study population patient establish suspected ALS Department Neurology , Aarhus University Hospital . Patients establish ALS participate undergo lumbar puncture part study . Subjects suspect suffer ALS undergo lumbar puncture part diagnostic work level sCD163 cerebrospinal fluid analyse . At Department Neurology , Aarhus University Hospital approximately 80 patient establish ALS . We expect 50 patient willing participate eligible inclusion ( 31-08-2015 ) . Furthermore , expect include 8 patient diagnosed ALS Department Neurology , Aarhus University Hospital study period . The control include patient various neurological symptom disease undergo lumbar puncture Department Neurology Aarhus University Hospital part diagnostic work-up irrespective study . In final analysis control include end either neurological disease neurological disease believe involve spinal fluid . We expect include 40-50 control . Recruitment Participants receive write oral information study . The oral information take place Department Neurology , Aarhus University Hospital . Moreover , pamphlet `` Forsøgspersoners rettigheder et sundhedsvidenskabeligt forskningsprojekt '' hand . Consultants department neurology give information , patient suspect ALS . Controls patient establish ALS receive information doctor department Neurology research year student Anne Sofie Vinther . It possible bring companion participant offer least 24 hour consider participation . Access patient record request , provide write information material . If new knowledge disadvantage participate study appear participant inform immediately . Moreover , participant inform evaluation study bring knowledge general health status patient , unless clearly reject patient . By end study possible participant contact study coordinator get information study result . All participant receive information research project ask give content participation . The participation imply extraction 5-6 ml spinal fluid blood sample ( 30ml ) , use analysis sCD-163 . Participants receive form payment , receive compensation transportation . Inclusion criterion : ALS Patients diagnosed ALS patient suspect ALS . Age &gt; 18 Controls Age &gt; 18 Exclusion criterion ( group ) : Acute infection include neuroinfection Other disorder know elevated level sCD163 Disorders treatment contraindicate lumbar puncture . Other establish neurological disorder . At time diagnostic work-up consequently research project respect patient mental physical condition . The research project carry accord Act Processing Personal Data , furthermore , project submit common regional information system Region Midtjylland . Analysis The spinal fluid serum analyse Department Clinical Biochemistry , Aarhus University Hospital . The spinal fluid blood sample deposit research biobank Aarhus University Hospital . It plan biochemical analysis perform sample collect . At end project , sample pseudo anonymised . Due possibility develop new knowledge area , sample deposit biobank 5 year project finish . The concentration sCD-163 spinal fluid serum analyze already establish technique Department Clinical Biochemistry , Aarhus University Hospital . Examination The examination consist medical history clinical examination . We use Revised ALS functional rating scale ( ALSFRS-R ) , rating instrument monitor progression disability patient ALS . Information medical record include use project include past medical history , actual use drug , result biochemical analysis brain imaging , result ALSFRS-R , result electromyography , abnormality clinical examination conclusion diagnostic work-up . Power Statistical analysis Since investigator pilot data ( n=7 ) show 50 % increase level CD163 cerebrospinal fluid ALS patient inclusion 40 patient expect enable detection small difference also serum relation CD163 clinical finding . The program ANOVA use statistical analysis . Parametric non-parametric test use depend normal distribution data . In statistical analysis 5 % level significance use . Perspectives It importance identify prognostic biomarkers ALS . The pathology ALS still unknown seem inflammation crucial factor process . In several study , sCD163 show regulated large range inflammatory diseases together investigator promise pilot data sCD163 potential marker ALS . ( 4 ) The assessment drug efficacy ALS remain clinically base , rely measure rate disease progression utilization ALS rating scale-revised ( ALSFRS-R ) . Such clinical scale may insensitive , especially early stage disease process . The development reliable quantifiable biomarkers remain elusive ALS , development prognostic biomarkers would crucial effective evaluation therapeutic agent early stage development . Ethical consideration The test perform patient involve research project lumbar puncture blood sample . It involve risk perform lumbar puncture , include post lumbar puncture headache incidence 12 % , common young patient . Most frequently , headache short duration may cure application blood-patch . Moreover , lumbar puncture cause temporary lumbar pain accumulation blood underneath skin . There low risk bleed epidural space compression spinal nerve even low risk infection ( meningitis meningoencephalitis ) . However , important underscore lumbar puncture part routine diagnostic workup Department Neurology Aarhus University Hospital . In consideration low risk involve project , bad prognosis disease potential improve diagnosis treatment future patient ALS consider project ethically acceptable . Publication Positive , negative well inconclusive result study publish . The result write article publication English write peer review journal .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>ALS control ( lumbar puncture department ) &lt; 18 year Other CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>spinal fluid</keyword>
	<keyword>CD163</keyword>
</DOC>